Nature:再证明食用抗氧化剂会促进癌症转移

2015-10-21 佚名 生物谷

                                (图片来源:美国德州大学西南医学中心)   来自美国德州大学西南医学中心儿童研究所的研究人员进行了一项研究,他们发现相比于正常细胞,癌细胞从抗氧化物得到的获益

                               
(图片来源:美国德州大学西南医学中心)
 
来自美国德州大学西南医学中心儿童研究所的研究人员进行了一项研究,他们发现相比于正常细胞,癌细胞从抗氧化物得到的获益更多,这一发现增加了人们对于癌症病人食用饮食中抗氧化物的担心。(生物谷之前曾报道抗氧化剂会加速小鼠皮肤癌细胞转移。
 
癌细胞转移是癌细胞从原发部位传播到身体其他部分的过程,是导致多数癌症病人死亡的重要原因。该研究团队发现对癌症小鼠模型进行抗氧化物处理会使癌细胞扩散更快。相关研究结果发表在国际学术期刊Nature上。
 
长久以来人们已经知道癌细胞从一个部位向身体其他部位传播是一个非常低效的过程,绝大多数进入血液中的癌细胞最终都不能存活。
 
在这项研究中,研究人员发现如果转移性黑色素瘤细胞受到高水平氧化应激刺激,会导致大部分转移性癌细胞发生死亡,而用抗氧化物对小鼠进行处理会帮助转移性黑色素瘤细胞存活,促进癌细胞转移。
 
Dr. Morrison说道:"抗氧化物对人体有益的观点非常强大,一些临床试验也给癌症病人进行抗氧化物处理,但在其中一些研究中,研究人员发现接受抗氧化物处理的病人死亡得更快,因此他们不得不终止了研究。我们的数据表明其中的原因可能是这样的:癌细胞会从抗氧化物中获得更多受益。"未患癌的健康人可能可以很好地得到抗氧化物的保护,降低正常代谢过程产生的活性氧化分子对机体造成的损伤。
 
虽然这项研究结果还没有在人体中得到验证,但研究人员仍然提出:应该用促氧化物质治疗癌症,并且癌症病人不应在饮食中补充大量抗氧化物质。
 
这项研究为癌症治疗增加了新的可能性。

原文出处:
 
Elena Piskounova,Michalis Agathocleous,Malea M. et al.Oxidative stress inhibits distant metastasis by human melanoma cells.Nature.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
    2017-04-01 哈夫

    ?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
    2015-11-02 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
    2016-01-30 yilibaisha

    有深度。。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    观点总有不同

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=184371, encodeId=c0ab1843e149, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/03/49a8b8e59b1110232178c436948997ae.jpg, createdBy=90151681386, createdName=哈夫, createdTime=Sat Apr 01 21:36:05 CST 2017, time=2017-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880844, encodeId=0e7b1880844e9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 16:10:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949367, encodeId=dce9194936e65, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 25 00:10:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62275, encodeId=5615622e569, content=有深度。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 20:59:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59824, encodeId=b7c3598240a, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59825, encodeId=89795982594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:57:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49452, encodeId=be6b4945281, content=观点总有不同, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 17:58:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379084, encodeId=9f9a13e908462, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489343, encodeId=b8cd14893432d, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Fri Oct 23 00:10:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40061, encodeId=4c35400615e, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Wed Oct 21 11:23:00 CST 2015, time=2015-10-21, status=1, ipAttribution=)]
    2015-10-21 lixh1719

    0

相关资讯

Sci Transl Med:抗氧化剂可加快肿瘤细胞转移速度

当我们想到抗氧化的作用时,我们经常把它与民众健康和充满活力等联系在一起。你是否认为,水果和蔬菜中富含抗氧化剂是一件喜大普奔的好事情?然而,在瑞典哥德堡大学萨尔格学院的研究人员对老鼠进行的一项新近研究表明,抗氧化剂可加快黑色素瘤患者在体内的转移速度,并使转移速度加倍。这项研究发表在《Science Translational Medicine》杂志。 在所有皮肤癌患者中,黑色素瘤患者所占比重不足2%

ARS:抗氧化剂或成为潜在的帕金森疾病疗法

近日,来自乔治亚健康科学大学的研究者的最新研究报道,一种新型强大的抗氧化剂有一天将有可能成为治疗帕金森疾病的潜在药物。这种抗氧化剂为合成的三萜类化合物,可以阻止帕金森疾病的发展。相关研究成果刊登在了近日的国际杂志Antioxidants & Redox Signaling上。 研究者Thomas和其同事使用抗氧化剂药物来支持Nrf2,从而可以阻止帕金森病人脑细胞中所产生的多巴胺的消失。N

NEJM:抗氧化剂如何加速癌症发生

近几十年来,世界各地追求健康的人们食用抗氧化剂补品和富含抗氧化剂的食物,他们认为这是一个健康和长寿之路。 然而关于抗氧化剂补品的临床试验一再打破消费者的希望即抗氧化剂能减少患癌症的风险。几乎所有的相关实验都没有表现出任何它能抗癌的作用。事实上,在一些试验中抗氧化剂补品与特定癌症的发生率增加相关联。在一项试验中,吸烟者吸取额外的β-胡萝卜素会患有更高风险的肺癌发生率。 刊登在《新英格兰医学杂志》

Gut:饮食中抗氧化剂摄入或阻断胰腺癌发病风险

近日,刊登在国际杂志Gut上的一项研究报告指出,增加饮食中抗氧化剂(维生素C、E、硒)的深入可以帮助2/3的人们切断发展为胰腺癌的风险。世界范围内胰腺癌每年可致超过25万人死亡。每年在英国有7500人被诊断出患上了胰腺癌。胰腺癌的预后效果是所有癌症中最差的,预后5年之后,仅仅有3%的人会幸存下来,当然了基因、吸烟和II型糖尿病也是影响因子,但是饮食占据着很大一部分原因。 研究者在1993年至19

Evolution:禁食疗法弊端再添新证据

纵观历史,人们一直在寻找长生不老之法,不管是从饮食还是服用维生素药片上,人们尝试了很多种方法;如今,来自英国巴斯大学的研究人员通过研究表示,抗老化疗法比如服用抗氧化剂或限制饮食等仅对抗衰老具有短暂的效应,而且其也存在一定的风险,相关研究刊登于国际杂志Evolution上。近年来,一种名为间歇性禁食(Intermittent Fasting)或者5:2饮食的一种策略广为流行,名人和媒体都认为这种饮食

脑震荡的潜在疗法——抗氧化剂疗法

近日,来自西弗吉尼亚大学(West Virginia University)的研究人员通过研究表明,抗氧化剂或许在脑震荡的长期效应上扮演着重要作用,而且其或许可以为开发脑震荡的新型疗法提供帮助。 脑震荡在运动员和士兵中较为常见,据估计在美国每年有大约340万的脑震荡患者,而口服补充剂的开发或许可以潜在改善一定比例脑震荡患者的脑部功能;脑震荡往往会引发慢性的损伤性脑病,脑部损伤通常会导致慢性损